for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.A

Latest Trade

6.72USD

Change

-0.33(-4.68%)

Volume

3,656

Today's Range

6.59

 - 

6.79

52 Week Range

6.11

 - 

18.96

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Inovio Receives Authorization To Conduct Phase 3 Efficacy Trial Of COVID-19 DNA Vaccine Candidate

Aug 26 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO RECEIVES AUTHORIZATION TO CONDUCT PHASE 3 EFFICACY TRIAL OF ITS COVID-19 DNA VACCINE CANDIDATE, INO-4800.INOVIO PHARMACEUTICALS INC - INOVIO'S GLOBAL PHASE 3 EFFICACY TRIAL RECEIVES AUTHORIZATION TO PROCEED FROM BRAZIL; OTHER COUNTRIES TO FOLLOW.INOVIO PHARMACEUTICALS INC - INOVIO TO CONDUCT INNOVATE PHASE 3 EFFICACY TRIAL WITH PARTNER ADVACCINE IN AREAS OF WORLD IN NEED OF COVID-19 VACCINES.INOVIO PHARMACEUTICALS - RECEIVED AUTHORIZATION FROM BRAZIL'S ANVISA TO CONDUCT PHASE 3 EFFICACY TRIAL OF COVID-19 DNA VACCINE CANDIDATE INO-4800.INOVIO - GLOBAL PHASE 3 SEGMENT OF PHASE 2/3 CLINICAL TRIAL TO EVALUATE EFFICACY OF INO-4800 IN TWO-DOSE REGIMEN ADMINISTERED ONE MONTH APART.

Inovio Reports Second Quarter 2021 Financial Results

Aug 9 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.39.Q2 EARNINGS PER SHARE ESTIMATE $-0.25 -- REFINITIV IBES DATA.TOTAL REVENUE WAS $273,000 FOR THREE MONTHS ENDED JUNE 30, 2021, COMPARED TO $267,000 FOR SAME PERIOD IN 2020.INOVIO PHARMACEUTICALS - AS OF JUNE 30, 2021, CASH AND CASH EQUIVALENTS & SHORT-TERM INVESTMENTS WERE $443.7 MILLION VERSUS $411.6 MILLION AS OF DECEMBER 31, 2020.CONTINUES TO EVALUATE AND ASSESS IMPACT NEW CIRCULATING STRAINS OF SARS-COV-2 HAVE ON IMMUNE PROFILE ELICITED BY INO-4800.

Inovio Expands Partnership With Advaccine To Conduct Global Phase 3 Trial OF COVID-19 VACCINE

June 8 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO EXPANDS PARTNERSHIP WITH ADVACCINE TO CONDUCT GLOBAL PHASE 3 EFFICACY TRIAL OF COVID-19 DNA VACCINE CANDIDATE, INO-4800.INOVIO PHARMACEUTICALS - PHASE 3 EFFICACY TRIAL PLANNED TO COMMENCE THIS SUMMER IN AREAS OF WORLD UNDERSERVED BY VACCINES.INOVIO PHARMACEUTICALS - CO & ADVACCINE INTEND TO SHARE EQUALLY TOTAL COST OF PLANNED GLOBAL PHASE 3 TRIAL, WHICH IS ESTIMATED TO BE ABOUT $100 MILLION.

Inovio Pharmaceuticals Plans To Start Global Phase 3 Trial For COVID-19 Vaccine Candidate This Summer

May 10 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.27.Q1 EARNINGS PER SHARE ESTIMATE $-0.18 -- REFINITIV IBES DATA.ASSESSING IMPACT THAT NEW CIRCULATING STRAINS OF SARS-COV-2 VIRUS HAVE ON IMMUNE PROFILE ELICITED BY INO-4800.PLANS TO INITIATE GLOBAL PHASE 3 TRIAL FOR INO-4800 THIS SUMMER.INOVIO - DEVELOPING NOVEL, PAN-COVID, SECOND-GENERATION VACCINE CANDIDATE, INO-4802, DESIGNED TO PROTECT AGAINST CURRENT, POTENTIALLY FUTURE VARIANTS.

Inovio Announces Positive Data From Phase 2 Segment Of Clinical Trial Evaluating Ino-4800, Its Covid-19 Dna Vaccine

May 10 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO ANNOUNCES POSITIVE DATA FROM PHASE 2 SEGMENT OF CLINICAL TRIAL EVALUATING INO-4800, ITS COVID-19 DNA VACCINE.INOVIO PHARMACEUTICALS INC - INO-4800 WAS SHOWN TO BE SAFE, WELL-TOLERATED AND IMMUNOGENIC IN ALL AGE GROUPS.INOVIO PHARMACEUTICALS INC - MAJORITY OF ADVERSE EVENTS (AES) WERE GRADE 1 AND GRADE 2 IN SEVERITY.INOVIO PHARMACEUTICALS INC - ADVERSE EVENTS DID NOT APPEAR TO INCREASE IN FREQUENCY WITH SECOND DOSE.INOVIO - GEOMETRIC MEAN FOLD RISE OF BINDING & NEUTRALIZING ANTIBODY LEVELS WERE STATISTICALLY SIGNIFICANTLY GREATER IN 2.0 MG DOSE GROUP.INOVIO PHARMACEUTICALS INC - T CELL IMMUNE RESPONSES MEASURED BY ELISPOT ASSAY WERE ALSO HIGHER IN 2.0 MG DOSE GROUP COMPARED TO 1.0 MG DOSE GROUP.INOVIO PHARMACEUTICALS - FOLLOWING SUBMISSION AND FDA CONCURRENCE TO PROCEED, COMPNY PLANS TO CONDUCT A GLOBAL PHASE 3 CLINICAL TRIAL FOR INO-4800.INOVIO PHARMACEUTICALS INC - PLANS TO FILE PRELIMINARY PHASE 2 RESULTS AND DEVICE DATA WITH U.S. FDA.

Inovio Planning For Ex-U.S. Global Phase 3 Trial For Ino-4800

April 23 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PLANNING FOR EX-US GLOBAL PHASE 3 TRIAL FOR INO-4800.INOVIO PHARMACEUTICALS INC - DOD JPEO-CBRND HAS NOTIFIED INOVIO THAT IT WILL DISCONTINUE FUNDING FOR PHASE 3 INO-4800 TRIAL.INOVIO PHARMACEUTICALS INC - INOVIO ADJUSTS INO-4800 CLINICAL DEVELOPMENT STRATEGY TO FOCUS ON GLOBAL UNMET COVID-19 VACCINE NEEDS.INOVIO - DOD JPEO-CBRND WILL DISCONTINUE FUNDING FOR PHASE 3 SEGMENT OF INNOVATE TRIAL, WHILE CONTINUING TO FUND COMPLETION OF ONGOING PHASE 2 SEGMENT.INOVIO PHARMACEUTICALS INC - INOVIO REMAINS WELL-POSITIONED TO SUPPORT BOTH PANDEMIC AND ENDEMIC VACCINE NEEDS WITH INO-4800 AND INO-4802.

Inovio Says In Q1 Completed Enrollment Of 400 Subjects In Phase 2 Segment Of Innovate Phase 2/3 Clinical Trial

March 1 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO REPORTS FOURTH QUARTER 2020 AND YEAR-END FINANCIAL RESULTS.INOVIO PHARMACEUTICALS - IN Q1 2021, INOVIO COMPLETED ENROLLMENT OF 400 SUBJECTS IN PHASE 2 SEGMENT OF INNOVATE PHASE 2/3 CLINICAL TRIAL.

Inovio Announces Positive Results From Reveal 1, A Phase 3 Pivotal Trial Evaluating VGX-3100

March 1 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO ANNOUNCES POSITIVE RESULTS FROM REVEAL 1, A PHASE 3 PIVOTAL TRIAL EVALUATING VGX-3100, ITS DNA-BASED HPV IMMUNOTHERAPY FOR THE TREATMENT OF HIGH-GRADE PRECANCEROUS CERVICAL DYSPLASIA CAUSED BY HPV-16 AND/OR HPV-18.INOVIO PHARMACEUTICALS INC - TRIAL ACHIEVED PRIMARY AND SECONDARY EFFICACY ENDPOINTS AMONG ALL EVALUABLE SUBJECTS IN PHASE 3 TRIAL.INOVIO PHARMACEUTICALS INC - INOVIO EXPECTS TO PRESENT REVEAL 1 FINDINGS AT A SCIENTIFIC MEETING THIS YEAR.INOVIO PHARMACEUTICALS INC - THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AND MOST ADVERSE EVENTS WERE SELF-RESOLVING.

Inovio Says Public Offering Of 17.7 Mln Common Shares At Price Of $8.5/Shr

Jan 20 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.INOVIO PHARMACEUTICALS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 17,700,000 SHARES OF ITS COMMON STOCK AT PUBLIC OFFERING PRICE OF $8.50 PER SHARE.

Inovio Pharmaceuticals - Preliminarily Estimates Cash, Equivalents & Short-Term Investments As Of Dec 31, 2020 Of About $412 Mln

Jan 20 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS - PRELIMINARILY ESTIMATES CASH, EQUIVALENTS & SHORT-TERM INVESTMENTS AS OF DEC 31, 2020 OF ABOUT $412 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up